Catalyst

Slingshot members are tracking this event:

With Cotellic + Zelboraf Combination Approved, Roche Looks to Develop Triple Combination Treatments With Atezolizumab

Source Link:
http://www.roche.com/irp160128-a.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The combination treatment of Cotellic and Zelboraf for the treatment of melanoma was recently approved in the US and EU.  With regulatory approval, Roche has begun Phase 1 trials with atezolizumab in addition to cotellic and zelboraf for possible triple combination treatments.
http://www.roche.com...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jan 28, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Cotellic, Zelboraf, Atezolizumab, Triple Combination Treatment, Melanoma
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.